Not a good buy right now for an impatient investor: the stock is near resistance with no proprietary “strong buy” signal, while options positioning (OI) leans defensive.
Risk/reward looks skewed to limited near-term upside into earnings (2026-02-19 pre-market) versus downside if results/guidance disappoint.
Best stance: Hold/avoid new entries at current levels; a better entry would typically be closer to support (~133 or ~131), but since you’re unwilling to wait, the direct call is: do not buy now.
Technical Analysis
Trend: Bullish structure with moving averages aligned positively (SMA_5 > SMA_20 > SMA_200), suggesting an established uptrend.
Momentum: MACD histogram slightly negative (-0.00291) but “negatively contracting,” implying downside momentum is fading rather than accelerating.
RSI: 61.36 (neutral-to-mildly bullish), not yet overbought, but not a “washed-out” entry either.
Levels: Pivot 132.981; Resistance R1 134.739 and R2 135.824; Support S1 131.224 (then S2 130.139). With price ~133.8–134.0, it’s closer to resistance than support, which limits an impatient entry’s edge.
Pattern-based stats: Model suggests a positive drift (80% chance of +1.36% next day; +3.32% next week; +5.77% next month), but this is modest versus earnings-event risk.
Sentiment read: Open-interest put/call at 3.2 is notably put-heavy (defensive/hedged positioning), which is not a clean “risk-on” backdrop.
Activity: Very light volume (todays_volume 2; put volume 0), so the volume put/call (0.0) is not very informative today.
Volatility: IV (30d) 18.59 vs historical vol 17.63; IV percentile 33.86 and very low IV rank (4.63) suggest options are relatively cheap vs the past year—more consistent with calm/low-fear pricing than panic, but not a strong bullish tell by itself.
Technical Summary
Sell
1
Buy
9
Positive Catalysts
and BTIG Buy (PT
suggest upside if execution remains solid.
Neutral/Negative Catalysts
implies notable hedging/caution.
Financial Performance
Latest quarter provided: 2025/Q3.
Revenue: $524.417M, down -0.78% YoY (slight top-line contraction).
Net income: $124.437M, up +9.53% YoY (bottom-line improvement).
EPS: 2.26, up +6.60% YoY (earnings growth remains positive).
Gross margin: 50.28%, down -6.46% YoY (margin compression is a watch item even as EPS rose).
Overall: Quality is okay (earnings up), but growth is not clean (revenue down, margins down), which makes paying up near resistance less attractive right now.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend (last ~2 months): Mixed-to-cautious.
Bullish/positive: BTIG kept Buy (PT trimmed to 156 from 157 on 2026-01-30); Morgan Stanley kept Overweight and raised PT to 146 from 139 (2026-01-21) after upgrading in Dec.
Neutral: UBS kept Neutral and cut PT to 129 from 135 (2025-12-17).
Bearish: Wells Fargo downgraded to Underweight with PT 118 (down from 129) on 2026-01-20, citing valuation premium and normalized forward growth.
Wall Street “pros vs cons” snapshot: Pros = steady regulated utility profile + supportive bullish targets from MS/BTIG; Cons = credible valuation/risk-reward pushback from Wells + neutral UBS stance, making the consensus less compelling for chasing at current price.
Influential/politician activity: No recent congress trading data available; hedge funds and insiders are reported Neutral with no significant recent trends.
Wall Street analysts forecast IDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IDA is 142.17 USD with a low forecast of 129 USD and a high forecast of 157 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast IDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IDA is 142.17 USD with a low forecast of 129 USD and a high forecast of 157 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
2 Hold
0 Sell
Moderate Buy
Current: 135.400
Low
129
Averages
142.17
High
157
Current: 135.400
Low
129
Averages
142.17
High
157
BTIG
Alex Kania
Buy
downgrade
$157 -> $156
AI Analysis
2026-01-30
Reason
BTIG
Alex Kania
Price Target
$157 -> $156
AI Analysis
2026-01-30
downgrade
Buy
Reason
BTIG analyst Alex Kania lowered the firm's price target on Idacorp to $156 from $157 and keeps a Buy rating on the shares as part of a broader research note previewing 2025 results for Utilities. Upbeat earnings calls could contrast against cautious investors, the analyst tells investors in a research note.
Morgan Stanley
David Arcaro
Overweight
maintain
$139 -> $146
2026-01-21
Reason
Morgan Stanley
David Arcaro
Price Target
$139 -> $146
2026-01-21
maintain
Overweight
Reason
Morgan Stanley analyst David Arcaro raised the firm's price target on Idacorp to $146 from $139 and keeps an Overweight rating on the shares. The firm is updating its Regulated & Diversified Utilities / IPPs in North America under its coverage, noting utilities underperformed the S&P's return in December, the analyst tells investors.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IDA
